Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 337 in MET Amplified Solid Tumors
NCT02016534Phase 2Terminated
- Sponsor
- Amgen
- Start
- Feb 2014
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 18
01
Overview
A Phase 2 trial of AMG-337 in gastric adenocarcinoma, esophageal adenocarcinoma (EAC), gastroesophageal junction adenocarcinoma, solid tumor, sponsored by Amgen. Started Feb 2014; status: terminated.
02
Drugs
AMG-337
03
Conditions
gastric adenocarcinomaesophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinomasolid tumor
Beyond the preview
Go deeper on NCT02016534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02016534.